BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$7.84

From 52W high−27.36%

Volume9.77M

Market cap$2.06B

P/E (TTM)—

P/S (TTM)2.2x

Div yield—

Key dataOct 19, 2026

Open

$7.84

From 52W high

−27.36%

Volume

9.77M

Market cap

$2.06B

ValuationView details →

P/E (Fwd)

12.8x

EV/EBITDA

−7.0x

P/E (TTM)

—

RSI (14)

41.5

MomentumView details →

1D Return

+3.59%

YTD Return

+2.85%

SummaryUpdated Jun 1, 2026

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a biotechnology company founded in 1986 and headquartered in Durham, North Carolina. The company went public in 1994 and has evolved from a drug discovery platform focused on structure-based drug design into a commercial-stage biopharmaceutical company. BioCryst specializes in developing oral, small-molecule medicines for rare diseases, with its flagship product ORLADEYO becoming a significant commercial success in treating hereditary angioedema. The company has transitioned from a research-focused entity burning substantial cash to approaching profitability, driven primarily by the strong commercial performance of its lead drug.

Ask drillr about BIOCRYST PHARMACEUTICALS INC →

ValuationView details →

P/E (Fwd)

12.8x

P/E (TTM)

—

EV/EBITDA

−7.0x

EV/Sales

2.3x

P/S (TTM)

2.2x

P/B (TTM)

−4.5x

ProfitabilityView details →

Gross Margin

23.52%

Net Margin

−40.90%

EBITDA Margin

−32.21%

ROE (TTM)

84.68%

ROA (TTM)

−68.96%

Asset Turnover

1.84x

GrowthView details →

Revenue YoY

+68.72%

EPS YoY

—

FCF YoY

+2165.77%

Revenue CAGR 3Y

+47.82%

EPS CAGR 3Y

+393.02%

EBITDA YoY

—

MomentumView details →

1D Return

+3.59%

YTD Return

+2.85%

1Y Return

+15.76%

RSI (14)

41.5

vs 50D SMA

−10.62%

vs 200D SMA

−7.95%

Capital & dividendView details →

Debt/Equity

−0.90x

Current Ratio

2.32x

Quick Ratio

2.29x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.30

EPS Surprise

94.55%

Beats (12Q)

7/12

Next Q EPS Est

$0.11

Avg Surprise (4Q)

356.97%

Rev Surprise

19.08%

Financials snapshotView financials →

Revenue (TTM)

940.61M

Net Income (TTM)

−384.67M

Op. CF (TTM)

359.87M

Next earningsNov 2, 2026 →

Latest newsMore news →

BioCryst Pharmaceuticals formed a seven-member Scientific Advisory Board to support its rare disease R&D pipeline.15d ago

BioCryst announced that Japan approved ORLADEYO for pediatric hereditary angioedema patients aged 2 and older, expanding availability of the oral prophylactic therapy.56d ago

Similar companies

Vericel CorporationVCEL Mabpharm Limited02181.HK Agios Pharmaceuticals, Inc.AGIO Vera Therapeutics, Inc.VERA Pharvaris N.V.PHVS SELLAS Life Sciences Group, Inc.SLS Find similar companies →

Latest newsMore news →

BioCryst Pharmaceuticals formed a seven-member Scientific Advisory Board to support its rare disease R&D pipeline.15d ago BioCryst announced that Japan approved ORLADEYO for pediatric hereditary angioedema patients aged 2 and older, expanding availability of the oral prophylactic therapy.56d ago BioCryst Pharmaceuticals began shipping ORLADEYO oral pellets to pediatric patients on August 3, 2026.76d ago